Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet (2013) 7.25

Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med (2014) 7.07

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA (2011) 5.54

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Association of aspirin use with major bleeding in patients with and without diabetes. JAMA (2012) 4.94

Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med (2009) 4.91

Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med (2004) 4.66

Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation (2002) 4.56

Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med (2010) 4.40

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. Ann Intern Med (2002) 4.24

Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med (2004) 4.17

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10

Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2007) 4.09

New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol (2007) 3.87

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (2009) 3.83

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.78

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care (2003) 3.68

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62

Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med (2009) 3.60

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol (2012) 3.42

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35

Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA (2009) 3.35

Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med (2009) 3.14

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97

Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89

Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med (2010) 2.88

Providing high-quality care for limited English proficient patients: the importance of language concordance and interpreter use. J Gen Intern Med (2007) 2.86

Looking forward, looking back: assessing variations in hospital resource use and outcomes for elderly patients with heart failure. Circ Cardiovasc Qual Outcomes (2009) 2.80

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64

Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer (2010) 2.61

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50

A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J (2007) 2.42

CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med (2008) 2.40

Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2004) 2.31

Haemoglobin targets: we were wrong, time to move on. Lancet (2007) 2.26

Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet (2007) 2.25

Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23

Comorbidity and competing risks for mortality in men with prostate cancer. Cancer (2011) 2.17

Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol (2008) 2.17

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J (2004) 2.09

Purging iron from the heart. Br J Haematol (2004) 2.07

Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med (2003) 2.05

Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol (2013) 2.04

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials (2007) 1.86

Multidimensional Prognostic Index based on a comprehensive geriatric assessment predicts short-term mortality in older patients with heart failure. Circ Heart Fail (2009) 1.83

Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab (2006) 1.81

Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis (2010) 1.81

The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail (2010) 1.78

Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail (2003) 1.77

Measuring quality of care in patients with multiple clinical conditions: summary of a conference conducted by the Society of General Internal Medicine. J Gen Intern Med (2007) 1.77

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood (2006) 1.76

Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood (2012) 1.74

Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem (2006) 1.74

Selecting indicators for the quality of diabetes care at the health systems level in OECD countries. Int J Qual Health Care (2006) 1.69

Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med (2011) 1.69

Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab (2010) 1.69

Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care (2002) 1.68

Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer (2007) 1.68

Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Crit Care Med (2007) 1.68

Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood (2012) 1.65